3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia
4
Vomiting
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, B-Cell
3
Hodgkin Disease
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Hairy Cell
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Cyclophosphamide
21
fludarabine phosphate
18
Whole-Body Irradiation
17
Methotrexate
17
Tacrolimus
15
Peripheral Blood Stem Cell Transplantation
15
Mycophenolic Acid
13
Dexamethasone
11
Vincristine
10
Etoposide
10
Antilymphocyte Serum
10
Calcium Dobesilate
9
Busulfan
9
Rituximab
8
Doxorubicin
8
merphos
7
Filgrastim
7
Cytarabine
7
Sirolimus
6
Prednisone
6
Melphalan
6
Granulocyte Colony-Stimulating Factor
6
Cyclosporine
6
pegaspargase
5
dexamethasone acetate
5
dexamethasone 21-phosphate
5
prednylidene
4
deltacortene
4
auricularum
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
Diphenhydramine
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts